O
CLDX icon

OrbiMed’s Celldex Therapeutics CLDX Stock Holding History

OrbiMed’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-58,800
Closed -$2.33M – 117
2023
Q4 		$2.33M Buy
+58,800
New +$1.73M 0.05% 94
2022
Q3 		– Sell
-112,700
Closed -$3.04K – 134
2022
Q2 		$3.04K Sell
112,700
-293,400
-72% -$8.52M 0.06% 121
2022
Q1 		$13.8M Hold
406,100
– – 0.22% 85
2021
Q4 		$15.7M Sell
406,100
-8,200
-2% -$357K 0.2% 97
2021
Q3 		$22.4M Buy
+414,300
New +$19.4M 0.25% 90
2020
Q4 		– Sell
-625,000
Closed -$9.27M – 153
2020
Q3 		$9.27M Hold
625,000
– – 0.12% 112
2020
Q2 		$8.13M Buy
+625,000
New +$2.77M 0.11% 109
2015
Q2 		– Sell
-40,000
Closed -$16.7M – 140
2015
Q1 		$16.7M Sell
40,000
-97,480
-71% -$34.9M 0.14% 85
2014
Q4 		$37.6M Sell
137,480
-7,960
-5% -$1.98M 0.36% 59
2014
Q3 		$28.3M Hold
145,440
– – 0.3% 62
2014
Q2 		$35.6M Sell
145,440
-11,067
-7% -$2.5M 0.42% 51
2014
Q1 		$41.5M Buy
156,507
+69,134
+79% +$26.5M 0.51% 46
2013
Q4 		$31.7M Buy
+87,373
New +$33.7M 0.47% 47

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

OrbiMed's CLDX Position: Q1 2024 in Review

OrbiMed sold out of Celldex Therapeutics (CLDX) in Q1 2024, closing a stake of 58,800 shares — an estimated $2.33M sold.

OrbiMed first reported a position in CLDX in Q4 2013 and held it in 13 quarters. The position peaked at $41.5M in Q1 2014. 197 funds tracked by Wall St. Rank hold CLDX as of Q1 2024.

  • OrbiMed reported no remaining Celldex Therapeutics position as of Q1 2024 after selling out during the quarter.
  • OrbiMed sold 58,800 Celldex Therapeutics shares in Q1 2024, an estimated $2.33M.
  • OrbiMed first reported a position in Celldex Therapeutics in Q4 2013 and held it in 13 quarters.
  • OrbiMed's Celldex Therapeutics position peaked at $41.5M in Q1 2014.
  • 197 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2024.

Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.